Latest Idera Pharmaceuticals Inc. Stories

2008-10-16 09:00:43

Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that it will present preclinical data from studies on its autoimmune disease program at the 4th Annual Meeting of the Oligonucleotide Therapeutics Society being held at the Harvard Medical School Conference Center in Boston, October 15-18, 2008. The Company's presentations describe studies of novel compounds targeted to Toll-like Receptors (TLRs), including the evaluation of TLR antagonist compounds in preclinical models of autoimmune...

2008-10-01 09:00:09

Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), today announced preliminary data from the first part of a Phase 2 clinical study conducted by the Company of IMO-2055 monotherapy in patients with metastatic or recurrent clear cell renal carcinoma (RCC). The primary objective was not achieved in the study. The primary objective was tumor response based on RECIST (Response Evaluation Criteria In Solid Tumors). Secondary objectives included time to progression, survival and safety. Progression-free...

2008-06-16 09:00:10

Idera Pharmaceuticals (Nasdaq: IDRA), a biopharmaceutical company focused on developing therapeutics targeting Toll-Like Receptors (TLRs), today announced the formation of an Autoimmune Disease Scientific Advisory Board. "We are pleased to have the participation of distinguished clinicians and researchers with extensive experience in the field of autoimmune diseases and biomarkers," said Sudhir Agrawal, D. Phil., Chief Executive Officer and Chief Scientific Officer. "Our TLR antagonist...

Word of the Day
  • Wasting away as a result of abstinence from food.
The word 'abrosia' comes from a Greek roots meaning 'not' and 'eating'.